Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection

[11] Brenner B.G., Oliveira M., Doualla-Bell F., Moisi D., Ntemgwa F., Et al., HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture, AIDS, 20, (2006)

[12] Subbarao S., Otten R., Ramos A., Jackson E., Adams D., Et al., Chemoprophylaxis with oral tenofovir disoproxil fumarate (TDF) delays but does not prevent infection in rhesus macaques given repeated rectal challenges of SHIV, 12th Conference on Retroviruses and Opportunistic Infections, (2005)

[13] Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Et al., Propagation and dissemination of infection after vaginal transmission of Simian Immunodeficiency Virus, J Virol, 79, pp. 9217-9227, (2005)

[14] Van 't Wout A.B., Ran L.J., Nijhuis M., Tijnagel J.M., Groot T.D., Et al., Efficient inhibition of both syncytium-inducing and non-syncytium- inducing wild-type HIV-1 by lamivudine in vivo, AIDS, 12, pp. 1169-1176, (1998)

[15] Marcelin A.-G., Fandre P., Pavie J., Schmidely N., Wirden M., Et al., Clinically relevant genotype interpretation of resistance to didanosine, Antimicrob Agents Chemother, 49, pp. 1739-1744, (2005)

[16] Sproat M., Pozniak A.L., Peeters M., Winters B., Hoetelmans R., Et al., The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine, Antivir Ther, 10, pp. 357-361, (2005)

[17] Whitcomb J.M., Parkin N.T., Chappey N., Hellmann N., Petropoulos C.J., Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates, J Infect Dis, 188, pp. 992-1000, (2003)

[18] Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Et al., Viral load and heterosexual transmission of human immunodeficiency virus type 1, N Engl J Med, 342, pp. 921-929, (2000)

[19] Cohen M.S., Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis, Lancet, 351, SUPPL. 3, pp. 5-7, (1998)

[20] Katzenstein T.L., Eugen-Olsen J., Hofmann B., Benfield T., Pedersen C., Et al., HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type, J Acquir Immune Defic Syndr Hum Retrovirol, 16, pp. 10-14, (1997)

[11] Brenner B.G., Oliveira M., Doualla-Bell F., Moisi D., Ntemgwa F., Et al., HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture, AIDS, 20, (2006)

[12] Subbarao S., Otten R., Ramos A., Jackson E., Adams D., Et al., Chemoprophylaxis with oral tenofovir disoproxil fumarate (TDF) delays but does not prevent infection in rhesus macaques given repeated rectal challenges of SHIV, 12th Conference on Retroviruses and Opportunistic Infections, (2005)

[13] Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Et al., Propagation and dissemination of infection after vaginal transmission of Simian Immunodeficiency Virus, J Virol, 79, pp. 9217-9227, (2005)

[14] Van 't Wout A.B., Ran L.J., Nijhuis M., Tijnagel J.M., Groot T.D., Et al., Efficient inhibition of both syncytium-inducing and non-syncytium- inducing wild-type HIV-1 by lamivudine in vivo, AIDS, 12, pp. 1169-1176, (1998)

[15] Marcelin A.-G., Fandre P., Pavie J., Schmidely N., Wirden M., Et al., Clinically relevant genotype interpretation of resistance to didanosine, Antimicrob Agents Chemother, 49, pp. 1739-1744, (2005)

[16] Sproat M., Pozniak A.L., Peeters M., Winters B., Hoetelmans R., Et al., The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine, Antivir Ther, 10, pp. 357-361, (2005)

[17] Whitcomb J.M., Parkin N.T., Chappey N., Hellmann N., Petropoulos C.J., Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates, J Infect Dis, 188, pp. 992-1000, (2003)

[18] Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Et al., Viral load and heterosexual transmission of human immunodeficiency virus type 1, N Engl J Med, 342, pp. 921-929, (2000)

[19] Cohen M.S., Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis, Lancet, 351, SUPPL. 3, pp. 5-7, (1998)

[20] Katzenstein T.L., Eugen-Olsen J., Hofmann B., Benfield T., Pedersen C., Et al., HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type, J Acquir Immune Defic Syndr Hum Retrovirol, 16, pp. 10-14, (1997)